On October 6, 2022 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting in Boston, MA, from November 10-12, 2022 (Press release, Imvax, OCT 6, 2022, View Source [SID1234621762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, Imvax will present data providing new insights into the mechanism of action of the company’s most advanced product candidate, IGV-001, for the treatment of glioblastoma. The company also will share in vivo data supporting the antitumor activity of Imvax’s tumor-derived immunotherapy platform for ovarian, liver and bladder cancers.